5,6-二甲基-1,2,3,4-四氢-吡啶 | 412320-62-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5,6-二甲基-1,2,3,4-四氢-吡啶
• 英文名称: 5,6-dimethyl-1,2,3,4-tetrahydro-pyridine
• 英文别名: 5,6-Dimethyl-1,2,3,4-tetrahydro-pyridin；5,6-Dimethyltetrahydropyridine；5,6-dimethyl-1,2,3,4-tetrahydropyridine
• CAS: 412320-62-8
• 化学式: C₇H₁₃N
• mdl: MFCD19218118
• 分子量: 111.187
• InChiKey: CHXZJEVKLSRVMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,6-二甲基-1,2,3,4-四氢-吡啶 在 水 、 羟胺 作用下， 生成 6-amino-3-methyl-hexan-2-one oxime
  参考文献：
  名称：

  Lipp; Widnmann, Justus Liebigs Annalen der Chemie, 1915, vol. 409, p. 123

  摘要：

  DOI：
• 作为产物：
  描述：

  6-溴-3-甲基己烷-2-酮 在 氨 作用下， 生成 5,6-二甲基-1,2,3,4-四氢-吡啶
  参考文献：
  名称：

  Sachs, Chemische Berichte, 1899, vol. 32, p. 62

  摘要：

  DOI：

文献信息

• Novel Heterocyclic Compounds as Bromodomain Inhibitors
  申请人：Liu Shuang

  公开号：US20140179648A1

  公开（公告）日：2014-06-26

  The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

  本公开涉及一些化合物，这些化合物通过结合溴结构域对BET蛋白功能进行抑制，并且它们在治疗中的应用。
• HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS
  申请人：Yu Chongxi

  公开号：US20100040548A1

  公开（公告）日：2010-02-18

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  该发明提供了一种新型高渗透性复合物（HPC）或高渗透性前药（HPP）的组合物，包括抗微生物和抗微生物相关化合物，这些化合物能够以高渗透效率穿越生物屏障。HPP能够在穿越生物屏障后转化为母药活性药物或药物代谢物，从而可以治疗母药或代谢物所能治疗的疾病。此外，HPP能够到达母药可能无法进入或在目标区域获得足够浓度的区域，从而提供新的治疗方法。HPP可以通过各种给药途径向受试者施用，例如，局部给药到病情作用部位以高浓度，或者系统给药到生物体内并以更快速度进入全身循环。
• Cyclic compounds
  申请人：Yamada Koichiro

  公开号：US20080027037A1

  公开（公告）日：2008-01-31

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  公式（I）的环状化合物或其药学上可接受的盐，其中X为═CH—或═N—，Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等，R1为较低的烷氧基、氨基、含N原子的杂环环或含N原子的杂环环取代的羟基（每个都可选地取代），R2为较低的烷基氨基，可选地取代芳基基团、可选地取代的较低的烷氧基、取代芳香族含N原子的杂环环的较低的烷氧基，R3为芳基基团、含N原子的杂环环、较低的烷基、较低的烷氧基、环状较低的烷氧基、含N原子的杂环环取代的羟基或氨基（每个都可选地取代），R3和Y中的取代基可结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• Pyrimidine Derivative Condensed with a Non-Aromatic Ring
  申请人：Yonetoku Yasuhiro

  公开号：US20080070896A1

  公开（公告）日：2008-03-20

  There are provided new pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety, and the like or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

  提供了一些新的嘧啶衍生物，其与二氢噻吩、二氢呋喃、环烷基等非芳香环结构缩合，或其药学上可接受的盐缩合；以及一种含有该化合物作为活性成分的制药组合物。这些化合物表现出对胰岛素分泌的促进活性和对高血糖的活性。因此，基于这些作用，包含这些化合物作为活性成分的制药组合物可用于治疗和/或预防胰岛素依赖性糖尿病（1型糖尿病）、非胰岛素依赖性糖尿病（2型糖尿病）、胰岛素抵抗性疾病、肥胖症等。
• 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS
  申请人：KOGA YOSHIHISA

  公开号：US20100022523A1

  公开（公告）日：2010-01-28

  The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R 1 is a C1-6 alkyl group which may be substituted, R 2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R 3 is a hydrogen atom or a C1-6 alkyl group, R 4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

  本发明涉及一种新型3-氨基苯酰胺化合物，其化学式如下，能够有效抑制vanilloid受体亚型1（VR1）的活性（其中，例如，R1是C1-6烷基，可以被取代，R2是氢原子，C1-6烷基或C1-6烷氧基，可以被取代，R3是氢原子或C1-6烷基，R4是C1-6烷基，C1-6烷氧基或卤代C1-6烷基，m是1到5的整数，P是碳或杂环）。该药物组合物包括3-氨基苯酰胺化合物或其药学上可接受的盐作为活性成分，对于治疗VR1活性相关的疾病，如疼痛、急性疼痛、慢性疼痛、神经性疼痛、类风湿性关节炎疼痛和神经痛等具有益处。